The tumor immune microenvironment in patients exhibiting high SF3A2 expression was notably deficient in most immune cells, indicative of an immune desert microenvironment, often referred to as a "cold tumor." Notably, CRC patients exhibiting elevated SF3A2 expression demonstrated a suboptimal response to anti-tumor immunotherapy. The gene discussed is SF3A2; the disease is colorectal carcinoma.